215600.KQ
SillaJen, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 2,410.00
−2.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.8B | 9.2B | 3.9B | 3.9B | 5.0B |
| Cost of Revenue | 24.4B | 27.7B | 3.2B | 2.5B | 23.8B |
| Gross Profit | (6.7B) | (18.5B) | 727.3M | 1.5B | (18.8B) |
| Operating Expenses | |||||
| R&D Expense | 18.7B | — | 14.5B | 10.2B | 9.4B |
| SG&A Expense | 16.5B | 21.1B | 17.8B | (5.1B) | 16.0B |
| General & Admin Expense | 2.8B | 3.2B | 2.8B | 2.5B | 2.3B |
| Selling & Marketing Expense | 16.8B | 18.0B | 15.0B | 10.6B | 13.8B |
| Other Expenses | (15.8B) | (14.0B) | (4.8B) | 16.7B | (19.8B) |
| Total Operating Expenses | 19.4B | 7.1B | 27.5B | 21.8B | 5.7B |
| Cost and Expenses | 36.9B | 34.7B | 30.7B | 25.4B | 29.5B |
| Operating Income (EBIT) | (26.1B) | (25.5B) | (26.8B) | (21.5B) | (24.4B) |
| Non-Operating | |||||
| Interest Income | 3.3B | 3.3B | 3.3B | 2.7B | 2.1B |
| Interest Expense | 355.4M | 903.4M | 1.8B | 1.7B | 2.1B |
| Net Interest Income | 2.9B | 2.4B | 1.5B | 1.0B | 69.6M |
| Other Non-Op Income/Expense | 2.5B | 1.8B | 327.1M | 1.3B | 545.2M |
| Non-Operating Income (excl Interest) | (1.3B) | — | (2.1B) | (3.0B) | (2.6B) |
| EBT (Pre-Tax Income) | (23.7B) | (23.7B) | (26.4B) | (20.2B) | (23.9B) |
| Income Tax Expense | 427.7M | 313.2M | 84.6M | 188.0M | 691.7M |
| Bottom Line | |||||
| Net Income | (24.1B) | (24.0B) | (26.5B) | (20.4B) | (24.6B) |
| Earnings from Cont. Ops | (24.1B) | (24.0B) | (26.5B) | (20.4B) | (24.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.0B) | (24.0B) | (26.5B) | (20.4B) | (24.6B) |
| Per Share | |||||
| Basic EPS | (₩174) | (₩176) | (₩220) | (₩180) | (₩221) |
| Diluted EPS | (₩174) | (₩176) | (₩220) | (₩180) | (₩221) |
| Revenue Per Share | ₩78 | ₩68 | ₩33 | ₩35 | ₩45 |
| Shares | |||||
| Basic Shares Outstanding | 138.5M | 136.7M | 120.6M | 113.2M | 111.1M |
| Diluted Shares Outstanding | 138.5M | 136.7M | 120.6M | 113.2M | 111.1M |
| Profitability Metrics | |||||
| EBITDA | (24.5B) | (24.7B) | (23.7B) | (17.4B) | (20.6B) |
| D&A | 920.9M | 866.2M | 939.2M | 1.1B | 1.2B |
| EBIT | (25.4B) | (25.5B) | (24.6B) | (18.5B) | (21.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026